{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:12:12Z","timestamp":1761707532938,"version":"3.40.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"Suppl. 1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2000]]},"abstract":"Intratumoral metabolism and synthesis of estrogens are considered to play very important roles in the pathogenesis and development of various sex steroid-dependent neoplasms including breast and endometrial carcinoma. 17\u03b2-Hydroxysteroid dehydrogenase (17\u03b2-HSD) isozymes catalyze the interconversion of estradiol (E<sub>2<\/sub>) and estrone (E<sub>1<\/sub>), and thereby serve to modulate the tissue levels of bioactive E<sub>2<\/sub>. 17\u03b2-HSD type 1 primarily catalyzes the reduction of E<sub>1<\/sub> to E<sub>2<\/sub>, whereas 17\u03b2-HSD type 2 primarily catalyzes the oxidation of E<sub>2<\/sub> to E<sub>1<\/sub>. In the human breast and its disorders, 17\u03b2-HSD type 1 is expressed in proliferative diseases without atypia, atypical ductal hyperplasia, ductal carcinoma in situ and invasive ductal carcinoma. 17\u03b2-HSD type 2 is not detected in any of the lesions. In addition, 17\u03b2-HSD type 1 coexpression is significantly correlated with estrogen receptor status in invasive ductal carcinoma cases. These results indicate that breast carcinoma can effectively convert E<sub>1<\/sub>, produced as a result of in situ aromatization, to E<sub>2<\/sub>, a biologically potent estrogen, and exerts estrogenic actions on tumor cells through the estrogen receptor. On the other hand, in the human endometrium, 17\u03b2-HSD type 2 is expressed, but not 17\u03b2-HSD type 1. 17\u03b2-HSD type 2 is expressed in the secretory phase but not in any proliferative phase in the endometrial mucosa. The enzyme is expressed in 75% of endometrial hyperplasias and 37% of carcinoma cases. In endometrial carcinoma cases, a significant inverse correlation has been detected between17\u03b2-HSD type 2 immunoreactivity and age (p < 0.02). These results indicate that oxidation of E<sub>2<\/sub> to E<sub>1<\/sub> is dominant in endometrial carcinoma, 17\u03b2-HSD types 1 and 2 play an important role in the regulation of in situ estrogen production in breast and endometrial carcinoma.<\/jats:p>","DOI":"10.1159\/000055281","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T19:06:20Z","timestamp":1050433580000},"page":"5-12","source":"Crossref","is-referenced-by-count":37,"title":["17-Beta-Hydroxysteroid Dehydrogenase in Human Breast and Endometrial Carcinoma"],"prefix":"10.1159","volume":"59","author":[{"given":"Hironobu","family":"Sasano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,11,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(91)90026-2"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(88)80548-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(81)90280-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(80)90117-X"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.267.7.941"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0956"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/55281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/55281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:36:03Z","timestamp":1745469363000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000055281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":7,"journal-issue":{"issue":"Suppl. 1","published-online":{"date-parts":[[2000,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000055281","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2000]]}}}